Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer, Merck Execs Share Emerging Markets Strategies - Windhover's Pharmaceutical Strategic Alliances Conference (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

During the recent Pharmaceutical Strategic Alliances Conference in New York, Pfizer's Emerging Markets Business Unit President Jean-Michel Halfon and Merck's Chief Strategy Officer and Emerging Markets R&D Senior VP Merv Turner discussed priorities in tackling emerging markets. In part one, the execs outlined the steps companies should take to set up operations in emerging markets and in this second part they share their experiences in building a presence in China.

You may also be interested in...



Hot Opportunities In The African Emerging Markets - A Look At South Africa (Part 1 of 2)

Although the fast-growing South African pharmaceutical market is dominated by local generic firms, multinational pharma companies are also seeing significant growth through new initiatives and product launches, said investment firm Credit Suisse in a September report based on IMS Health data

Hot Opportunities In The African Emerging Markets - A Look At South Africa (Part 1 of 2)

Although the fast-growing South African pharmaceutical market is dominated by local generic firms, multinational pharma companies are also seeing significant growth through new initiatives and product launches, said investment firm Credit Suisse in a September report based on IMS Health data

Merck And BGI Sign Global Deal Focused On Biomarkers, Genomics

After announcing the intent to form a partnership a year ago, Merck & Co. announced Sept. 13, a collaboration with BGI (formerly the Beijing Genomics Institute) for discovery and development of biomarkers and genomic technologies

Related Content

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel